Nervgen Pharma (NGEN) Accounts Payables (2024 - 2026)

Nervgen Pharma (NGEN) posted quarterly Accounts Payables of $4.3 million for Q1 2026, up 28.35% quarter-over-quarter from $3.3 million in Q4 2025.

Nervgen Pharma (NGEN) Accounts Payables (2024 - 2026) Analysis & Trends

Nervgen Pharma (NGEN) has reported Accounts Payables for 3 consecutive years, with $4.3 million the latest figure, recorded in Q1 2026.

In Q1 2026, Accounts Payables changed N/A year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $4.3 million (changed N/A YoY), while the FY2025 annual figure was $3.3 million, down 5.58% from the prior year.
Accounts Payables climbed to $4.3 million in Q1 2026 per NGEN's latest filing, from $3.3 million in the prior quarter.
Across five years, Accounts Payables topped out at $4.3 million in Q1 2026 and bottomed at $3.3 million in Q4 2025.
Historically, Accounts Payables has averaged $3.7 million across 3 years, with a median of $3.5 million in 2024.
On a YoY basis, Accounts Payables climbed as much as 5.58% in 2025 and fell as far as 5.58% in 2025.
Nervgen Pharma's Accounts Payables stood at $3.5 million in 2024, then declined by 5.58% to $3.3 million in 2025, then gained by 28.35% to $4.3 million in 2026.
Business Quant data shows NGEN's Accounts Payables at $4.3 million in Q1 2026, $3.3 million in Q4 2025, and $3.5 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Accounts Payables (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	429.50 Mn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.16 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.52 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	167.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	470.30 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	108.02 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	428.93 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	35.57 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	622.65 Mn
10	Nervgen Pharma	161.78 Mn	161.78 Mn	-	3.10 Mn

Download Data